Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetic profiles of sertraline in pregnancy as a predictor of postpartum depressive symptoms.

British journal of clinical pharmacologyยท2025
Same author

Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guรฉrin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.

The Journal of infectious diseasesยท2023
Same author

Age-dependent dysregulation of locus coeruleus firing in a transgenic rat model of Alzheimer's disease.

Neurobiology of agingยท2023
Same author

Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder.

The international journal of neuropsychopharmacologyยท2021
Same author

Effects of a cognitive stress challenge on myocardial perfusion and plasma cortisol in coronary heart disease patients with depression.

Stress and health : journal of the International Society for the Investigation of Stressยท2021
Same author

Quality Control of Busulfan Plasma Quantitation, Modeling, and Dosing: An Interlaboratory Proficiency Testing Program.

Therapeutic drug monitoringยท2021
Same journal

Genetic overlap between treatment-resistant schizophrenia and smoking initiation.

The international journal of neuropsychopharmacologyยท2026
Same journal

External Validation as the Critical Step for Predictive Biomarkers.

The international journal of neuropsychopharmacologyยท2026
Same journal

Viloxazine occupies the 5-HT2C receptor in the macaca fascicularis brain in vivo: A [11C]CIMBI-36 positron emission tomography study.

The international journal of neuropsychopharmacologyยท2026
Same journal

Divergent effects of interleukin-6 and ghrelin on remission and relapse in depression treatment.

The international journal of neuropsychopharmacologyยท2026
Same journal

Secondary Restless Legs Syndrome during psychopharmacological treatment: real-world evidence from a multinational pharmacovigilance program.

The international journal of neuropsychopharmacologyยท2026
Same journal

Recent cannabis exposure and acute nicotine effects: insights from randomized, double-blind, placebo-controlled intravenous nicotine studies.

The international journal of neuropsychopharmacologyยท2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

Localization of the Locus Coeruleus in the Mouse Brain
07:44

Localization of the Locus Coeruleus in the Mouse Brain

Published on: March 7, 2019

Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons.

Charles H K West1, James C Ritchie, Katherine A Boss-Williams

  • 1Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30306, USA.

The International Journal of Neuropsychopharmacology
|October 28, 2008
PubMed
Summary
This summary is machine-generated.

All effective antidepressant drugs tested decreased locus coeruleus (LC) neuron activity across therapeutic blood levels. Non-antidepressant drugs did not affect LC activity, supporting a common mechanism for antidepressant efficacy.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jun 28, 2026

Localization of the Locus Coeruleus in the Mouse Brain
07:44

Localization of the Locus Coeruleus in the Mouse Brain

Published on: March 7, 2019

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Previous research indicates effective antidepressant drugs reduce locus coeruleus (LC) neuron activity.
  • Limited data exist on drug blood levels in prior studies, suggesting potentially high concentrations.

Purpose of the Study:

  • To determine if antidepressants selectively blocking norepinephrine or serotonin reuptake decrease LC activity at therapeutically relevant blood levels.
  • To investigate the effects of mirtazapine, an alpha2 adrenergic receptor blocker, on LC activity.
  • To assess the specificity of LC response to antidepressants by testing non-antidepressant drugs.

Main Methods:

  • Chronic administration of desipramine, paroxetine, escitalopram, and mirtazapine via osmotic minipumps for 14 days.
  • Electrophysiological recording of LC spontaneous and sensory-evoked 'burst' firing under anesthesia.
  • Measurement of drug blood levels at the time of electrophysiological recording.

Main Results:

  • All tested antidepressant drugs consistently decreased both spontaneous and sensory-evoked LC firing.
  • This effect was observed across a wide range of therapeutic blood drug levels.
  • Non-antidepressant drugs did not exhibit a similar decrease in LC activity.

Conclusions:

  • The findings support the hypothesis that a common mechanism for effective antidepressant drugs involves decreasing locus coeruleus neuron activity.
  • This effect appears consistent across different classes of antidepressants at relevant therapeutic concentrations.